

## **CURRICULUM VITAE**

Geoffrey Justin Clark PhD

117 Ash Avenue, Pewee Valley, KY 40056

Office Tel: 502 852 4485

Office FAX: 502 852 3661

Email: gjclar01@louisville.edu

### **A. Education:**

09/82-07/85 University of Manchester, U.K., B.Sc., Biochemistry and Applied  
Molecular Biology (2.i)

10/85-07/89 University of Manchester, U.K., Ph.D., Molecular Oncology

### **B. Academic Appointments:**

1996-1998 Research Assistant Professor, Dept. Pharmacology, University of  
North Carolina at Chapel Hill, Chapel Hill, N.C.

1998-2006 Head, Signaling and Oncogenesis Laboratory, NCI, Cell and  
Cancer Biology Branch, Rockville, MD.

2006-2013 Associate Professor, Dept. Medicine, University of Louisville,  
J.G.Brown Cancer Center, Molecular Targets Group, Room 417  
CTR Building, 505 S. Hancock St., Louisville, KY. 40202

2014-present Associate Professor Dept. Pharmacology/Toxicology, University of  
Louisville, Room 417 CTR Building, 505 S. Hancock St.,  
Louisville, KY. 40202.

### **C. Other Positions and Employment:**

1982-1985 Undergraduate student, University of Manchester Institute of  
Science and Technology, UK. Dept. Biochemistry and Applied  
Molecular Biology

1985-1989 Graduate Student, University of Manchester, Department of  
Oncology, UK.

1989-1990 Postdoctoral Fellow, University of Southern California,  
Laboratory of Viral Oncology and AIDS, Los Angeles, CA.

- 1990-1992 Postdoctoral Fellow, La Jolla Cancer Research Foundation, La Jolla, CA.
- 1992-1995 Research Associate, Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC.

**D. Board certification**

Not Applicable

**E. Professional Memberships and Activities:**

Member of AACR  
 Member of Biochemical Society

Participation in Study Sections:

- 2006-20009: California Breast Cancer Research Program.  
 2007-present: CDMRP Breast Cancer Research Program.  
 2002-present: Ad Hoc reviewer Cancer Research Campaign UK.  
 2006-present: Ad Hoc reviewer MRC, UK.  
 2002-2004: Ad Hoc reviewer, NSF.  
 2009: Reviewer for Young Investigator grants, Italian Health Service.  
 2009-present: Reviewer for James and Esther King Biomedical Research Program and the Bankhead-Coley Cancer Research Program (University of Florida).  
 2009: Deutsche Forschungsgemeinschaft (German Research Foundation)  
 2010: NIH Study section (CAMP) Ad Hoc member.  
 2013-2014: JGBCC Study Section

Local Activities:

- 2006, 2008, 2012,2013,2014: Judge, Research Louisville  
 2007,2010-11,14: MD/PhD Summer Student Mentor  
 2014; Mentor for Institutional Development Award (IDeA) (PI: Dr. McClain)  
 2014: Mentor for Pharm/Tox R25

**F. Honors and Awards**

- 1985-1988: Science and Engineering Council CASE (Co-operation with Industry) Award  
 1991, 1993,  
 1996, 2000,  
 2002: Poster selected for oral presentation at the Annual Oncogene Meeting, Frederick, Maryland:  
 2000, 2001,

- 2002, 2003: NCI Technology Transfer Awards  
 2003: Chairman: Tumor Suppressor Section, Annual Oncogene meeting, Frederick, Maryland  
 2009: Chairman: Clinical Implications Section, 1st biannual RASSF family meeting, Banf, Canada.  
 20011: Chairman: Clinical Implications Session, 2<sup>nd</sup> biannual RASSF family meeting, Oxford, UK.  
 2011: Chairman, Session 2, Swine in Biomedical Research Conference, Chicago, IL.  
 2012: Scientist of the year Award, J.G Brown Cancer Center, University of Louisville

### **G. Assignments and Administrative services**

- 2008-2009: Organizer and host of *Poa Pratensis* Molecular Targets Seminar Series.  
 2008-2011: Thesis committee for PhD Student S. Biswas, Dept. Chemistry.  
 2009-2012: Thesis committee for PhD Student X. Huang, Dept. Chemistry.  
 2014- Thesis committee for PhD student Dominique Jones (Pharm/Tox)  
 2014- Thesis committee for PhD student Christopher Sidal (Pharm/Tox)  
 2014 Thesis committee for PhD student Nicole Jackson (Pharm/Tox)  
 2014- Thesis committee for PhD student Diana Avila (Pharm/Tox)  
 2014- Member Faculty Search Committee  
 2014- Graduate Student Affairs and Curriculum Committee (Pharm/Tox)  
 2014- Seminar Committee (Pharm/Tox)

### **H. Journal Editorial Boards, Advisory councils, Peer Reviewer**

- 2007-present: Editorial Board Member *Biochemical Journal*  
 2011-present: Editorial Board Member *Frontiers in Cancer Genetics*  
 2012: Special Guest Editor *Molecular Biology International*

2000-present: Reviewer for:

Mol. Cell Biol  
 Oncogene  
 Molecular Carcinogenesis  
 J. Cell Science  
 Clinical Cancer Research  
 Science STKE  
 Biochemistry  
 Proc. Nat. Acad. Sci.  
 Int. J. Cancer.  
 Exp. Cell Res.  
 Biochemical Journal  
 Cancer Research  
 Animal Biotechnology

## **I. Board Memberships:**

2009-present: Medical Advisory Board, Kidney Cancer Association

## **J. Teaching**

- 1995-1997: Developed and taught “Oncogenes” module for Pharmacology Dept. UNC-Chapel Hill graduate students.  
1999-2006: Trained 5 National Cancer Institute pre-IRTA graduate students  
2007-present: Designed and taught BIOC-675 Cancer Biology course “Metastasis” module at the University of Louisville.  
2014- Animal Models Module, Pharmacology/Toxicology graduate Course.

## **K. Presentations**

### **Oral Presentations at meetings:**

#### **National**

- 1992: AACR annual meeting, San Diego CA  
1991, 1993,  
1996, 2000,  
2002: Annual Oncogene Meeting, Frederick, MD  
2003: Gordon Conference on Ras-like small GTPases, Ventura, CA  
2006: FASEB summer research conference on small GTPases, Saxtons River, VT.  
2007: Mechanisms & Models of Cancer Meeting, Salk Inst. CA  
20013: Invited Speaker, third biannual Symposium on RASSF family proteins, Monterey CA.

#### **International**

- 2003: Invited speaker, Molecular Cardiology Meeting, University of Manchester, UK,  
2009: Invited speaker, First biannual RASSF Symposium, Banff, Canada.  
2011: Invited speaker, Second biannual Symposium on RASSF family proteins, Oxford, England.

## **L. Patent Applications:**

**USSN 60/251,971**; Filed: December 7, 2000.

*Compositions and Methods Related to the MINNI Tumor Suppressor Gene and Protein.*

Inventors: Clark, G. and Vos, M.

**NIH Ref. No. E-293-00/0**; Filed: June 4, 2001.

*Rig, A Novel Ras-Related Gene.*

Inventors: Clark, G., Vos, M., and Ellis, C.A.

USSN 60/323,274; Filed: September 19, 2001.

*MAXPI is a Ras Effector and Novel Tumor Suppressor of the MINN1 Family.*

Inventors: Clark, G. and Vos, M.

## **Support**

### **Previously Funded:**

**USAMRMC Breast Cancer Initiative** (Career Development Award).

PI, 10% effort

Term: 1997-2001. \$50,000 per annum

*Cloning of novel oncogenes involved in Breast Cancer : DAMMD17-97-7050*

(Grant detained at UNC after recruitment to the NIH intramural program).

### **NIH R29 FIRST AWARD.**

PI., 30% effort

Term: 1997-2002. \$70,000 per annum

*Regulation of Ras Effectors: CA72644-10*

(Grant returned to NIH upon recruitment to the intramural program).

### **NCI Intramural Funds**

PI. 100% effort

1998-2006. ~\$233,0000 per annum

### **NIH COBRE GRANT**

Co-PI, 30% effort

Term: 2006-2010, \$138,000 Direct per annum

*Control of tumor growth by Ras family proteins:*

1P20 RR18733

### **USAMRMC Ovarian Cancer Research Initiative**

PI, 10% effort

Term: 2008-2009, \$70,000 Direct per annum

*Exploration of the Use of Epigenetic Therapy to Enhance the Effectiveness of Taxol Treatment:*

OC073121

### **Kentucky Lung Cancer Research Program**

PI, 10% effort

Term 2009-2010 \$45,000 Total

*The role of Nore1a in lung cancer*

### **Kentucky Science and Engineering Council**

Co-PI 0% effort

Term 2010-2012                      \$6,000 Total

*Nanoparticle Carriers for Thermally-Induced Drug Release*

**USAMRMC (Peer Reviewed Medical Research Program)**

PI, 20% effort

Term: 2009-June 2013                      \$162,000 Direct costs per annum

*The role of the RASSF1A tumor suppressor in kidney cancer*

PR-081350

**Currently Funded**

**NIH/NCI R01**

PI, 30% effort

Term : 2010- 04/30/2015

*The Role of the Ras effector Nore1a in tumor suppression*

R01 CA133171-01A2

**NIH R01 Eureka Award**

PI, 20% effort

Term 2010-05/31/2015 (No cost extension)

*Oncopigs as a better model for human cancer*

1R01CA153132-01

**National Swine Resource and Research Center (NSRRC) (New strain creation program)**

Co-PI,

*Term: 2010-2015 (Gratis generation of transgenic animal)*

*Generation of a Porcine model for Breast Cancer*

**NIH COBRE PILOT GRANT**

PI, 5% effort

Term: 2013-2015,

*The development of Novel Ras antagonists to inhibit cancer*

1P20 RR18733

**Pending**

**NCI R01**

PI: 30% effort

Term: 2015-2020

The Role and Relevance of RASSF1A inactivation in Ras driven cancer

## **CDMRP**

PI: 20% effort  
Term 2015-2018

The development of RalGDS inhibitors to treat MPNST

## **CDMRP**

PI: 20% effort  
Term 2015-2017

Radiation Induced Cancer and the RASSF1A A(133)S SNP

## **N. Clinical Service**

Not applicable

## **O. Publications**

### **a. Peer Reviewed Publications:**

1. Khosravi-Far, R., **Clark, G.J.**, Abe, K., Cox, A.D., McLain, T., Lutz, R.J., Sinensky, M. and Der, C.J. (1992). Ras (CXXX) and Rab (CC/CXC) prenylation signal sequences are unique and functionally distinct. *J. Biol. Chem.*, 267, 24363-24368.
2. **Clark, G.J.**, Quilliam, L.A., Hisaka, M.M. and Der, C.J. (1993). Differential antagonism of Ras biological activity by catalytic and Src homology domains of Ras GTPase activation protein. *Proc. Natl. Acad. Sci. USA*, 90: 4887-4891.
3. **Clark, G.J.**, and Der, C.J. (1995). Aberrant function of the Ras signal transduction pathway in human breast cancer. *Breast Cancer Res. Treatment*, 35, 133-144.
4. Kinch, M.S., **Clark, G.J.**, Der, C.J. and Burridge, K. (1995). Tyrosine phosphorylation regulates the adhesions of ras-transformed breast epithelia. *J. Cell. Biol.*, 130, 461-471.
5. Khosravi-Far, R., Solski, P.A., **Clark, G.J.**, Kinch, M.S. and Der, C.J. (1995). Activation of Rac and Rho, and mitogen activated protein kinases, are required for Ras transformation. *Mol. Cell. Biol.*, 15, 6443-6453.
6. **Clark, G.J.**, Kinch, M.S., Gilmer, T.M., Burridge, K. and Der, C.J. (1996). Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancer. *Oncogene*, 12, 169-176.
7. **Clark, G.J.**, Drugan, J.K., Terrell, R.S., Bradham, C., Der, C.J., Bell, R.M. and 8.

Campbell-Burk, S. (1996). Inhibition of Ras function by peptides containing a consensus Ras binding sequence from Raf-1 and NF1. *Proc. Natl. Acad. Sci. USA*, 93, 1577-1581.

9. Oldham, S.M., **Clark, G.J.**, Gangarosa, L.M., Coffey, R.J. and Der, C.J. (1996) Activation of Raf/MAP kinase cascade is not sufficient for Ras transformation of RIE epithelial cells. *Proc. Natl. Acad. Sci. USA*, 93, 6924-6928.

10. Graham, S.M., Vojtek, A.B., Huff, S.Y., Cox, A.D., **Clark, G.J.**, Cooper, J.A. and Der, C.J. (1996) TC21 is activated by Ras guanine nucleotide exchange factors but causes transformation by Raf-independent signaling pathways. *Mol. Cell. Biol.* 16, 6132-6140.

11. **Clark, G.J.**, Westwick, J.K. and Der, C.J. (1997). p120 GAP modulates Ras Activation of Jun Kinases and transformation. *J. Biol. Chem.* 272, 1677-1681

12. Westwick, J.K., Lambert, Q., **Clark, G.J.**, Symons, M., Van Aelst, L., Pestell, R.G., and Der, C.J. (1997) Rac1 regulation of transformation, Gene expression and actin organization by multiple, PAK-independent pathways. *Mol. Cell Biol.* 17, 1324-1335.

13. **Clark, G.J.**, Kinch, M.S., Rogers-Graham K., Sebti, S., Hamilton A. and Der, C.J. (1997). The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. *J.Biol.Chem.* 272, 10608-10615

14. **Clark, G.J.**, Drugan, J.K., Rossman, K.L., Carpenter, J.W., Rogers-Graham, K., Fu, H., Der, C.J. and Campbell, S.L. (1997) 14-3-3 Zeta negatively regulates Raf-1 activity by interactions with the Raf-1 cysteine rich domain. *J.Biol.Chem.* 272, 20990-20993.

15. Della Rocca GJ, Mukhin, Y.V., Garnovskaya M.N., Daaka, Y., **Clark, G.J.**, Luttrell, L.M., Lefkowitz, R.J. and Raymond J.R. (1999) Serotonin 5-HT1A receptor Mediated Erk Activation requires Calcium/Calmodulin dependent Receptor Endocytosis. *J.Biol.Chem.* 274, 4749-4753

16. Williams J.G., Drugan J.K., Gwan-Su Y., **Clark G.J.**, Der C.J. and Campbell S.L. (2000) Elucidation of binding determinants and functional consequences of Ras/Raf- CRD binding *J.Biol.Chem.* 275, 22172-22179.

17. Drugan, J.K., Rogers-Graham K., Gilmer T., Campbell S.L., and **Clark, G.J.**, The Ras/p120 GAP interaction is regulated by the p120 GAP PH domain. (2000) *J.Biol.Chem.* Nov 10;275(45):35021-35027.

18. Vos, M., Ellis, C.A., Bell, A., Birrer, M.J. and **Clark G.J.** Ras utilizes the tumor suppressor RASSF1 as an effector to mediate apoptosis. (2000) *J.Biol.Chem.* 17;275(46):35669-35672

19. Weber, C.H., Walters, J., Leyton, J., Casibang, M., Purdom, S., Jensen, R.T., Coy, D.H.,



Ellis, C.A., **Clark, G.J.** and Moody, T.W. A bombesin receptor subtype-3 peptide increases nuclear oncogene expression in a MEK-1 dependent manner in human lung cancer cells. (2001) *Eu. J. Pharmacology* 412, 13-20.

20. Ellis, C.A. Vos, M.D., Howell, H., Vellacorsa T., Fults D.W., and **Clark, G.J.** Rig is a novel Ras-related protein and potential neural tumor suppressor. (2002) *Proc. Nat. Acad. Sci.* vol 99, no.15, pp 9876-9881

21. Ellis C.A., Vos M.D., Wickline, M., Riley, C., Vallecorsa T., Telford, W., Zujewski, J. and **Clark, G.J.** Tamoxifen and a farnesyl transferase inhibitor (FTI) synergize to promote growth inhibition and apoptosis in estrogen receptor (ER) positive human breast tumor cell lines. (2003) *Breast Cancer Res. And Treatment*, 78 59-67

22. Vos, M., Martinez, A., Ellis, C.A., Vallecorsa, T. and **Clark G.J.** The pro-apoptotic Ras effector Nore1 may serve as a Ras regulated tumor suppressor in the lung. (2003) *J. Biol. Chem.* 278, 21938-21943

23. Vos, M.D, Ellis, C.A., Elam, C., Ulku, A., Taylor, B.J., and **Clark G.J.** RASSF2 is a novel K-Ras specific effector and potential tumor suppressor. (2003) *J. Biol. Chem.* 278(30):28045-28051

24. Castro A.F., Rebhun, J.F., **Clark G.J** and Quilliam L.Q. Rheb binds the TSC2 tumor suppressor and promotes S6 kinase activation in a rapamycin and farnesylation dependent manner. (2003) *J. Biol. Chem.*; 278(35):32493-6.

25. Jindong Chen, Weng-Onn Lui, Michele D. Vos, **Geoffrey J. Clark**, Masayuki Takahashi, Jacqueline Schoumans, Sok Kean Khoo, David Petillo, Todd Lavery, Jun Sugimura, DewiAstuti, Chun Zhang, Susumu Kagawa, Eamonn Maher, Catharina Larsson, Arthur S. Alberts, Hiro-omi Kanayama, and Bin Tean Teh\* The t(1;3) breakpoint-spanning genes *LSAMP* and *NORE1* are involved in clear cell renal cell carcinomas. (2003) *Cancer Cell.* 4 (5) 405-413

26. Vos, M.D.; Dallol, A., Martinez, A., Elam, C., Taylor, B.J., Latif, F. and **Clark G.J.** A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability (2004) *Cancer Research.* 64 (12) 4244-50

27. Dallol A., Agathangelou A., Fenton, S.L., Ahmed-Choudry, J., Hesson, L, Vos, M.D., **Clark, G.J.**, Downward, J., Maher, E.R and Latif F. RASSF1A interacts with microtubule associated proteins and modulates microtubule dynamics. (2004) *Cancer Research* 64 (12):4112-6

28. Armesilla, A.L., Williams, J.C., Buch, M.H., Emerson, M., Cartwright, E.J., Oceandy, D., Gillies, S., Vos, M.D., **Clark, G.J.** and Neyses, L. . Novel functional interaction between the Plasma membrane Calcium pump 4b and the proapoptotic tumor suppressor RASSF1 (2004)

29. Eckfeld, K., Hesson, L., Vos, M.D., Bieche, I, Latif F., and **Clark G.J.**  
RASSF4/AD037 is a novel potential Ras effector/tumor suppressor of the RASSF family (2004)  
Cancer Research 64(23):8688-93.
  
30. Lebowitz PF, Eng-Wong J, Widemann BC, Balis FM, Jayaprakash N, Chow C, **Clark G**,  
Gantz SB, Venzon D, Zujewski J.  
A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and  
tamoxifen in metastatic breast cancer.  
Clin Cancer Res. (2005) Feb 1;11(3):1247-52.
  
31. Elam, C., Hesson L., Vos, M.D., Eckfeld, K., Ellis, C.A., Bell, A., Taylor, B.J., Krex,  
D., Birrer M.J., Latif, F. and **Clark G.J.**  
RRP22 is a farnesylated, nucleolar, Ras-related protein with tumor suppressor potential.  
Cancer Research : (2005) Apr 15;65(8):3117-25.
  
32. Leaner, V.D., Donniger, H., Ellis, C.A., **Clark G.J.** and Birrer M.J.. RasGRF1 is  
upregulated and required for Ras mediated signal transduction through PI3K in cJun/AP-1  
expressing cells.  
Mol. Cell. Biol : (2005) Apr 25 (8):3324-37.
  
33. Ahmed-Choudry A, J., Agathangelou A., Fenton, S.L., Riucketts, C., **Clark G.J.**,  
Maher, E.R and Latif F.  
Transcriptional regulation of cyclin A2 by RASSF1A through the enhanced binding of p120 E4F  
to the cyclin A2 promoter.  
Cancer Research : (2005) Apr 1;65(7) 2690-7.
  
34. Vos, M.D., Aganathalou, A., Eckfeld, K, Hesson, L. Latif, F and **Clark G.J.** The  
RASSF1A tumor suppressor activates Bax via MOAP-1  
J. Biol. Chem (2006) 24;281(8):4557-63
  
35. Adam Pickard; Mamta H Buch; Sheona E Gillies; **Geoffrey J Clark**; Elizabeth J  
Cartwright; Angel L Armesilla and Ludwig Neyses. Ras-Association Factor 1 - A Novel  
Antihypertrophic Protein in the Myocardium  
Circulation. (2006)114:II\_53.
  
36. Allen, N.P.C., Doninger H, Vos, M.D., Eckfeld, K., Hesson, L. Donninger, H., Gordon  
L, Birrer, M.J., Latif, F. and **Clark. G.J.**  
RASSF6 is a novel member of the RASSF family of tumor suppressors  
Oncogene (2007) April, 1-9
  
37. Geli, J., Kiss, N., Lanner, F., Foukakis, T., Natalishivili, N., Larsson, O., Kogen, P.,  
Hoog, A., **Clark, GJ.**, Eckstrom, T., Backdahl, M., Farnebo, F.,and Larsson, C. The ras effectors

Nore1a and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma. *Endocrine Related Cancer* (2007) Mar;14(1):125-34

38. Donninger, H., Vos, MD., **Clark, G.J.** The RASSF1A tumor suppressor  
*Journal of Cell Science* (2007). 320. 3163-3172

39. Cooper WN, Dickinson, RE, Dallol, A, Grigorieva, EV, Pavlova, TV, Hesson, LB, Bieche, I, Broggin, M, Maher, EM, Zabarovsky, ER, **Clark, G.J.**, Latif, F.  
Epigenetic regulation of the ras effector/tumor suppressor RASSF2 in breast and lung cancer.  
*Oncogene* . 2008 Mar 13;27(12):1805-11.

40. Geli, J. Kogner, P., Lanner, F., Natalishivilli, N., Juhlin, C., Kiss, N., **Clark, G.J.**, Ekstrom, T.J., Farnebo, F. and Larsson C. Assessment of NORE1A as putative tumor suppressor in Human Neuroblastoma. *Int. J. Can. Res.* 2008 Jul 15;123(2):389-94.

41. Diego F. Calvisi, Howard Donninger, Michele D. Vos, Michael Birrer, Laura Gordon, Virna Leaner, and **Geoffrey J. Clark**. The NORE1A tumor suppressor candidate modulates p21<sup>CIP1</sup> via p53. *Cancer Research*. 2009 Jun 1;69(11):4629-37

42. Donninger H, Hesson L, Vos M, Beebe K, Gordon, K, Sidransky, D, Wei Liu J, Schlegel T, Payne S, Hartmann A, Latif F and **Clark G.J.** The Ras effector RASSF2 controls the PAR-4 tumor suppressor.- *Mol. Cell Biol* 2010 Jun;30(11):2608-20)

43. Dominic P. Del Re, Takahisa Matsuda, Peiyong Zhai, Shumin Gao, **Geoffrey J. Clark**, Louise Van Der Weyden, and Junichi Sadoshima. RASSF1A is a novel regulator of cardiac fibrosis and dysfunction in response to pressure overload. *JCI*, 2010 Oct 1;120(10):3555-67

44. Souvik Biswas, Laura E. Gordon, Biswapriya Deb, **Geoffrey J. Clark** and Michael H. Nantz. Click Assembly of Magnetic Nanovectors for Gene Delivery  
*Biomaterials*, 2011 : 2011 Apr;32(10):2683-8

45. Howard Donninger, Nadia Allen, Adrianna Henson, Jennifer Pogue, Andrew Williams, Laura Gordon, Susannah Kassler, Thomas Dunwell, Farida Latif and **Geoffrey J. Clark**: Salvador is a tumor suppressor effector of RASSF1A with Hippo pathway independent functions. *J. Biol. Chem.* 2011 May 27;286(21):18483-91

46. Souvik Biswas, Ralph J. Knipp, Laura E. Gordon, Seshagiri R. Nandula, Sven-Ulrik Gorr, **Geoffrey J. Clark**, and Michael H. Nantz: Hydrophobic Oxime Ethers: A Versatile Class of pDNA and siRNA Transfection Lipids. *ChemMedChem* 2011, 6, 1–8.

47. Howard Donninger, Thibaut Barnoud, Nick Nelson, David Powel, Suzanna Kassler, Jennifer Clark, Tim C. Cummins, David Powel, Sarah Nyante, Robert C. Millikan and **Geoffrey J. Clark**. RASSF1A and the rs2073498 Cancer Associated SNP. *Frontiers in Cancer Genetics* 2011 Dec 1 (54) :1-7.

48. Susannah Kassler, Howard Donninger, Michael J. Birrer and **Geoffrey J. Clark**. RASSF1A and the Taxol response in Ovarian cancer. *Molecular Biology International*,2012:263267. Epub 2012 Apr 3.
49. Tarnowski M, Schneider G, Amann G, **Clark G**, Houghton P, Barr FG, Kenner L, Ratajczak MZ, Kucia M. RasGRF1 regulates proliferation and metastatic behavior of human alveolar rhabdomyosarcomas. *Int J Oncol*. 2012 Sep;41(3):995-1004. Epub 2012 Jun 28.
50. Christopher Arnette, Nadia Efimova, Xiadong Zhu, **Geoffrey J. Clark** and Irina Kaverina. Microtubule segment stabilization by RASSF1A is required for proper microtubule dynamics and Golgi integrity. *Mol Biol. Cell*, 2014 Mar; 25(6):800-10
51. Jun Yan, Goetz Kloecker, Chris Fleming, Richard Hansen, Xiaoling Hu, Chuanlin Ding, Yihua Cai, Xiang Dong, Howard Donninger, John W. Eaton and **Geoffrey J. Clark**. Human Polymorphonuclear Neutrophils Specifically Recognize Tumor Cells for Killing *Oncoimmunology*- 2014 *in press*
52. Jessica Mezzanott, Victoria Hill, M. Lee Schmidt, Dietmar Krex, Gabriele Schackert, Gerd P. Pfeifer Farida Latif and **Geoffrey J. Clark**. RASSF inactivation in brain metastases, a role for RASSF6 in metastatic melanoma. *Epigenetics*. 9:11, 1--8; November 2014
53. Howard Donninger, Jennifer A. Clark, Megan K. Monaghan, M. Lee Schmidt, Michele Vos and Geoffrey J. Clark. Cell cycle restriction is more important than apoptosis induction for RASSF1A tumor suppression. *J. Biol Chem*. 2014 Nov 7;289(45):31287-95
54. M.Lee Schmidt., Howard Donninger and **Geoffrey J. Clark**. Ras regulates SCF<sup>β-TrCP</sup> activity and specificity via its effector NORE1A. *J. Biol. Chem*. 2014 Nov 7;289(45):31102-10.
55. Howard Donninger, Jennifer Clark, Francesca Rinaldo, Katherine Hobbing, Nicholas Nelson, Thibaut Barnoud, M. Lee Schmidt Michele D, Vos, Brian Sils and **Geoffrey J. Clark**. The RASSF1A tumor suppressor regulates XPA mediated DNA repair. *Mol. Cell Biol*. 2015 Jan 1;35(1):277-87.
56. Howard Donninger, Diego F. Calvisi, Thibaut Barnoud, Jennifer Clark, M. Lee Schmidt, Michele D. Vos and **Geoffrey J. Clark**. NORE1A is a Ras senescence effector that controls the apoptotic/senescent balance of p53 via HIPK2. (2015) *J. Cell Biology*: *in press*
57. Stephanie J. Mattingly, Geoffrey J. Clark, Michael H. Nantz. Cationic Magnetoliposomes for Drug Delivery. *Langmuir*, *submitted*

## **b. Non-Peer Reviewed Publications**

1. **Clark, G.J.** and Der, C.J. (1993). Oncogenic activation of Ras proteins. In GTPases in Biology (Handbook of Experimental Pharmacology). (Editors Burton Dickey and Lutz Birnbaumer). Springer-Verlag, Chapter 18, pages 259-288.
2. **Clark, G.J.** and Der, C.J. (1995). *ras* proto-oncogene activation in human malignancy. In, Cellular Cancer Markers (C.T. Garrett and S. Sell, editors), 17-52.
3. **Clark, G.J.**, Cox, A.D., Graham, S.M. and Der, C.J. (1995). In vitro and in vivo assays for Ras Transformation. In Small GTPases and their regulators (W.E. Balch, C.J. Der and A. Hall, editors). Academic Press, Methods in Enzymology, vol. 255, 395-412.
4. Campbell, S.L., Khosravi-far, R., Rossman, K.L., **Clark, G.J.**, and Der, C.J. (1998). Complexity of Ras Signal Transduction. *Oncogene* 17, 17 1395-1423
5. **Clark, G.J.**, O'Bryan, J.P., and Der C.J. (2000). Ras signaling and Transformation in "Signaling Networks and Cell Cycle control: The Molecular Basis of Cancer and Other Diseases" (Gutkind, J.S. Editor). Humana Press. Chapter 12 pp 213-228
6. Ellis, C.A. and **Clark G.J.**, The importance of being K-Ras. (2000) *Cellular Signaling*. 12(7), 425-434
7. Reuther, G.W, Buss, J.E., Quilliam, L.A., **Clark, G.J.**, and Der, C.J. (2000) Analysis of the the function and regulation of proteins that mediate signal transduction by use of lipid-modified plasma membrane targeting sequences. *Academic Press. Methods in Ezymology* vol 327, 331-50
8. Urano J., Ellis C.A., **Clark, G.J.** and Tamanoi F., Characterization of Rheb functions by using Yeast and mammalian systems. *Academic Press, Methods in Enzymology*, (2001);333:217-31
9. Latif F and **Clark G.J.** The RASSF1A/tubulin connection. *Cancer Research Highlights*, June 2004
10. Vos, M.D and **Clark G.J.** The RASSF family of proteins *Methods in Enzymology* (2005);407:311-22
11. Schmidt. L and **Clark GJ**, Nore1a/RASSF5,. *Atlas Genet Cytogenet Oncol Haematol*. 2011, <http://atlasgeneticsoncology.org/Genes/RASSF5ID42059ch1q32.html>
12. **Clark GJ**, Baksh S, **Latif F**, Lim DS. RASSF Family Proteins. *Mol Biol Int*. Epub 2012 Dec 10.

